FLORENCE, Italy & PLANTATION, Fla.--(BUSINESS WIRE)--Goodwin Biotechnology, Inc. (GBI), of Plantation, Florida and Menarini Group, of Florence, Italy, have just announced the successful completion of a strategic co-operation for the manufacturing of the monoclonal antibody Abagovomab. This antibody is the active principle of the Menarini Group’s groundbreaking ovarian cancer vaccine, now in phase III clinical studies around the world.
